Over a week ago
Hot Stocks
Becton Dickinson…
Becton Dickinson announced that it has received 510(k) clearance from the FDA for the BD Vaginal Panel on the BD COR System, a diagnostic test that directly detects the three most common infectious causes of vaginitis using BD's high-throughput molecular diagnostic platform for large laboratories.
Show Hide Related Items >> <<
03/09/23 Moody's to appoint Vincent Forlenza chairman on April 18 02/21/23 Becton Dickinson announces FDA market approval for BD Onclarity HPV Assay 01/11/23 Becton Dickinson introduces BD Kiestra robotic track system 01/09/23 Becton Dickinson, CerTest Biotec announce EUA for molecular PCR assay for Mpox 02/02/23 Piper Sandler Becton Dickinson price target raised to $260 from $245 at Piper Sandler 01/03/23 BofA BofA downgrades Baxter to Neutral, prefers Becton Dickinson 01/03/23 BofA Becton Dickinson upgraded to Buy at BofA on double digit EPS growth 01/03/23 BofA Becton Dickinson upgraded to Buy from Neutral at BofA 02/02/23 Becton Dickinson ups FY23 adjusted EPS view to $12.07-$12.32 from $11.85-$12.10 02/02/23 Becton Dickinson reports Q1 adjusted EPS $2.98, consensus $2.68 11/10/22 Becton Dickinson sees FY23 adjusted EPS $11.85-$12.10, consensus $12.19 11/10/22 Becton Dickinson reports Q4 adjusted EPS $2.75, consensus $2.74 10/07/22 Becton Dickinson issues recall of sterilization containers, WSJ says 09/24/22 Microsoft among dividend stocks to beat inflation, rising rates, Barron's says 01/03/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/12/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/10/22 Fly Intel: Pre-market Movers 11/21/22 Early notable gainers among liquid option names on November 21st
Hot Stocks
Moody's Corporation …
Moody's Corporation (MCO) announced that Vincent Forlenza will be appointed Chairman of its Board of Directors on April 18 . Forlenza, former Chairman and CEO of Becton, Dickinson (BDX)and Company, joined Moody's Board of Directors in 2018 and currently serves as Lead Independent Director. He will succeed Raymond W. McDaniel, Jr., who will retire from Moody's board, having served as Chairman since January 2021 and as Moody's Chief Executive Officer from 2005 to 2020. Forlenza, 69, served as a director of Becton, Dickinson and Company (BD), a global medical technology company, from 2011 to April 2021 and as the Chairman of its board from 2012 to April 2021. He was BD's Chief Executive Officer from 2011 to January 2020 and President from 2009 to April 2017. Mr. Forlenza is chairman of the Board of Trustees of Lehigh University and serves as a director to both MARAbio Systems, Inc. and MNHI. He was previously the Chairman of AdvaMed, the medical device industry association and the Valley Hospital System in New Jersey.
Show Hide Related Items >> <<
01/09/23 Moody's names Francisco Martinez-Garcia chief DEI officer 12/11/22 Fly Intel: Top five weekend stock stories 12/01/22 Moody's to acquire SCRiesgo, terms undisclosed 09/26/22 W.P. Carey announces ratings upgrade to Baa1 by Moody's Investor Service $234.31 / -0.875 (-0.37%)
02/21/23 Becton Dickinson announces FDA market approval for BD Onclarity HPV Assay 01/11/23 Becton Dickinson introduces BD Kiestra robotic track system 01/09/23 Becton Dickinson, CerTest Biotec announce EUA for molecular PCR assay for Mpox 01/06/23 BD general counsel Samrat Khichi to leave, Michelle Quin named in acting role 02/01/23 RBC Capital Moody's price target raised to $350 from $329 at RBC Capital 02/01/23 Baird Moody's price target raised to $350 from $289 at Baird 02/01/23 Barclays Moody's price target raised to $300 from $275 at Barclays 02/01/23 Raymond James Moody's downgraded at Raymond James as ratings rebound priced in $234.31 / -0.875 (-0.37%)
02/02/23 Piper Sandler Becton Dickinson price target raised to $260 from $245 at Piper Sandler 01/03/23 BofA BofA downgrades Baxter to Neutral, prefers Becton Dickinson 01/03/23 BofA Becton Dickinson upgraded to Buy at BofA on double digit EPS growth 01/03/23 BofA Becton Dickinson upgraded to Buy from Neutral at BofA 01/31/23 Moody's sees FY23 EPS $9.00-$9.50, consensus $9.28 01/31/23 Moody's reports Q4 adjusted EPS $1.60, consensus $1.44 10/25/22 Moody's reports Q EPS $1.85 , consensus $2.02 10/25/22 Moody's reports Q EPS $1.85 , consensus $2.02 $234.31 / -0.875 (-0.37%)
02/02/23 Becton Dickinson ups FY23 adjusted EPS view to $12.07-$12.32 from $11.85-$12.10 02/02/23 Becton Dickinson reports Q1 adjusted EPS $2.98, consensus $2.68 11/10/22 Becton Dickinson sees FY23 adjusted EPS $11.85-$12.10, consensus $12.19 11/10/22 Becton Dickinson reports Q4 adjusted EPS $2.75, consensus $2.74 12/10/22 Microsoft, Arista among stocks that can survive a triple whammy, Barron's says $234.31 / -0.875 (-0.37%)
10/07/22 Becton Dickinson issues recall of sterilization containers, WSJ says 09/24/22 Microsoft among dividend stocks to beat inflation, rising rates, Barron's says $234.31 / -0.875 (-0.37%)
01/03/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/12/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/10/22 Fly Intel: Pre-market Movers $234.31 / -0.875 (-0.37%)
11/21/22 Early notable gainers among liquid option names on November 21st
Over a month ago
Hot Stocks
Becton Dickinson…
Becton Dickinson announced FDA market approval for the BD Onclarity HPV Assay to be used with the ThinPrep Pap Test.
Show Hide Related Items >> <<
01/11/23 Becton Dickinson introduces BD Kiestra robotic track system 01/09/23 Becton Dickinson, CerTest Biotec announce EUA for molecular PCR assay for Mpox 01/06/23 BD general counsel Samrat Khichi to leave, Michelle Quin named in acting role 12/14/22 GXO Logistics teams with BD Rowa to optimize storage, retrieval 02/02/23 Piper Sandler Becton Dickinson price target raised to $260 from $245 at Piper Sandler 01/03/23 BofA BofA downgrades Baxter to Neutral, prefers Becton Dickinson 01/03/23 BofA Becton Dickinson upgraded to Buy at BofA on double digit EPS growth 01/03/23 BofA Becton Dickinson upgraded to Buy from Neutral at BofA 02/02/23 Becton Dickinson ups FY23 adjusted EPS view to $12.07-$12.32 from $11.85-$12.10 02/02/23 Becton Dickinson reports Q1 adjusted EPS $2.98, consensus $2.68 11/10/22 Becton Dickinson sees FY23 adjusted EPS $11.85-$12.10, consensus $12.19 11/10/22 Becton Dickinson reports Q4 adjusted EPS $2.75, consensus $2.74 10/07/22 Becton Dickinson issues recall of sterilization containers, WSJ says 09/24/22 Microsoft among dividend stocks to beat inflation, rising rates, Barron's says 08/29/22 Becton Dickinson ordered to pay $4.8M over hernia-mesh claims, Bloomberg says 08/29/22 Becton Dickinson ordered to pay $4.8M over hernia-mesh claims, Bloomberg says 01/03/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/12/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/10/22 Fly Intel: Pre-market Movers 08/29/22 What You Missed On Wall Street On Monday 11/21/22 Early notable gainers among liquid option names on November 21st
Recommendations
Piper Sandler analyst…
Piper Sandler analyst Jason Bednar raised the firm's price target on Becton Dickinson to $260 from $245 and keeps a Neutral rating on the shares post the fiscal Q1 results. The company posted a solid performance to start fiscal 2023 its outlook for the year that suggests management's strategy is going to plan, the analyst tells investors in a research note. However, with the shares already trading above historical averages, Piper sees better near-term opportunities elsewhere for medtech investors.
Show Hide Related Items >> <<
01/11/23 Becton Dickinson introduces BD Kiestra robotic track system 01/09/23 Becton Dickinson, CerTest Biotec announce EUA for molecular PCR assay for Mpox 01/06/23 BD general counsel Samrat Khichi to leave, Michelle Quin named in acting role 12/14/22 GXO Logistics teams with BD Rowa to optimize storage, retrieval 01/03/23 BofA BofA downgrades Baxter to Neutral, prefers Becton Dickinson 01/03/23 BofA Becton Dickinson upgraded to Buy at BofA on double digit EPS growth 01/03/23 BofA Becton Dickinson upgraded to Buy from Neutral at BofA 12/12/22 Citi Becton Dickinson upgraded to Neutral from Sell at Citi 02/02/23 Becton Dickinson ups FY23 adjusted EPS view to $12.07-$12.32 from $11.85-$12.10 02/02/23 Becton Dickinson reports Q1 adjusted EPS $2.98, consensus $2.68 11/10/22 Becton Dickinson sees FY23 adjusted EPS $11.85-$12.10, consensus $12.19 11/10/22 Becton Dickinson reports Q4 adjusted EPS $2.75, consensus $2.74 10/07/22 Becton Dickinson issues recall of sterilization containers, WSJ says 09/24/22 Microsoft among dividend stocks to beat inflation, rising rates, Barron's says 08/29/22 Becton Dickinson ordered to pay $4.8M over hernia-mesh claims, Bloomberg says 08/29/22 Becton Dickinson ordered to pay $4.8M over hernia-mesh claims, Bloomberg says 01/03/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/12/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/10/22 Fly Intel: Pre-market Movers 08/29/22 What You Missed On Wall Street On Monday 11/21/22 Early notable gainers among liquid option names on November 21st
Earnings
Consensus $11.95. Raises…
Consensus $11.95. Raises FY23 revenue view to $19.1B-$19.3B from $18.6B-$18.8B, consensus $18.82B. The company said, "Revenue guidance now assumes base business currency-neutral revenue growth of 5.75% to 6.75% compared to 5.25% to 6.25% previously announced, which represents an increase of 50 basis points, or approximately $90 million at the mid-point. Our increased base business revenue guidance reflects continued momentum as we execute our BD 2025 growth strategy. Revenue guidance now assumes approximately $50 million to $100 million in COVID-only diagnostic testing revenues, which is a decrease of approximately $75 million at the mid-point compared to approximately $125 million to $175 million previously announced. Based on current rates, foreign exchange would represent a reduction of approximately 200 basis points to total company revenue growth compared to approximately 450 basis points previously announced, which represents a reduction in the estimated foreign currency headwind of approximately 250 basis points or approximately $480 million... Adjusted diluted EPS guidance includes an estimated impact from foreign currency of approximately 230 basis points based on current rates compared to 420 basis points previously announced, which represents a reduction in the estimated foreign currency headwind of approximately 190 basis points."
Show Hide Related Items >> <<
01/11/23 Becton Dickinson introduces BD Kiestra robotic track system 01/09/23 Becton Dickinson, CerTest Biotec announce EUA for molecular PCR assay for Mpox 01/06/23 BD general counsel Samrat Khichi to leave, Michelle Quin named in acting role 12/14/22 GXO Logistics teams with BD Rowa to optimize storage, retrieval 01/03/23 BofA BofA downgrades Baxter to Neutral, prefers Becton Dickinson 01/03/23 BofA Becton Dickinson upgraded to Buy at BofA on double digit EPS growth 01/03/23 BofA Becton Dickinson upgraded to Buy from Neutral at BofA 12/12/22 Citi Becton Dickinson upgraded to Neutral from Sell at Citi 02/02/23 Becton Dickinson reports Q1 adjusted EPS $2.98, consensus $2.68 11/10/22 Becton Dickinson sees FY23 adjusted EPS $11.85-$12.10, consensus $12.19 11/10/22 Becton Dickinson reports Q4 adjusted EPS $2.75, consensus $2.74 11/09/22 Notable companies reporting before tomorrow's open 10/07/22 Becton Dickinson issues recall of sterilization containers, WSJ says 09/24/22 Microsoft among dividend stocks to beat inflation, rising rates, Barron's says 08/29/22 Becton Dickinson ordered to pay $4.8M over hernia-mesh claims, Bloomberg says 08/29/22 Becton Dickinson ordered to pay $4.8M over hernia-mesh claims, Bloomberg says 01/03/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/12/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/10/22 Fly Intel: Pre-market Movers 08/29/22 What You Missed On Wall Street On Monday 11/21/22 Early notable gainers among liquid option names on November 21st
Earnings
Reports Q1 revenue…
Reports Q1 revenue $4.59B, consensus $4.52B. "Our strong performance in Q1 reflects the momentum of our BD 2025 strategy, driven by a combination of innovation and continued strong execution," said Tom Polen, chairman, CEO and president of BD. "Consistent, durable performance in our base business reflects our team's relentless focus on delivering category-leading products and transformative solutions that are helping our customers deliver quality and more cost-effective care to patients around the world. We believe that our strong execution, coupled with our winning portfolio, position BD to play a central role in reinventing care for a new era and creating sustained value for all stakeholders."
Show Hide Related Items >> <<
01/11/23 Becton Dickinson introduces BD Kiestra robotic track system 01/09/23 Becton Dickinson, CerTest Biotec announce EUA for molecular PCR assay for Mpox 01/06/23 BD general counsel Samrat Khichi to leave, Michelle Quin named in acting role 12/14/22 GXO Logistics teams with BD Rowa to optimize storage, retrieval 01/03/23 BofA BofA downgrades Baxter to Neutral, prefers Becton Dickinson 01/03/23 BofA Becton Dickinson upgraded to Buy at BofA on double digit EPS growth 01/03/23 BofA Becton Dickinson upgraded to Buy from Neutral at BofA 12/12/22 Citi Becton Dickinson upgraded to Neutral from Sell at Citi 11/10/22 Becton Dickinson sees FY23 adjusted EPS $11.85-$12.10, consensus $12.19 11/10/22 Becton Dickinson reports Q4 adjusted EPS $2.75, consensus $2.74 11/09/22 Notable companies reporting before tomorrow's open 10/07/22 Becton Dickinson issues recall of sterilization containers, WSJ says 09/24/22 Microsoft among dividend stocks to beat inflation, rising rates, Barron's says 08/29/22 Becton Dickinson ordered to pay $4.8M over hernia-mesh claims, Bloomberg says 08/29/22 Becton Dickinson ordered to pay $4.8M over hernia-mesh claims, Bloomberg says 01/03/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/12/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/10/22 Fly Intel: Pre-market Movers 08/29/22 What You Missed On Wall Street On Monday 11/21/22 Early notable gainers among liquid option names on November 21st
Hot Stocks
BD introduced a new,…
BD introduced a new, robotic track system for the BD Kiestra microbiology laboratory solution that automates lab specimen processing, which may help to reduce manual labor and wait time for results. The new BD Kiestra 3rd Generation Total Lab Automation System allows laboratories to create a custom and flexible total lab automation configuration to connect multiple BD Kiestra modules and is scalable to meet labs' unique and evolving needs. With multiple track options and choice of instruments to employ, labs can choose their automation entry point and configure the system to fit their individual workflow and physical lab space.
Show Hide Related Items >> <<
01/09/23 Becton Dickinson, CerTest Biotec announce EUA for molecular PCR assay for Mpox 01/06/23 BD general counsel Samrat Khichi to leave, Michelle Quin named in acting role 12/14/22 GXO Logistics teams with BD Rowa to optimize storage, retrieval 11/10/22 Becton Dickinson increases quarterly dividend 4.6% to 91c per share 01/03/23 BofA BofA downgrades Baxter to Neutral, prefers Becton Dickinson 01/03/23 BofA Becton Dickinson upgraded to Buy at BofA on double digit EPS growth 01/03/23 BofA Becton Dickinson upgraded to Buy from Neutral at BofA 12/12/22 Citi Becton Dickinson upgraded to Neutral from Sell at Citi 11/10/22 Becton Dickinson sees FY23 adjusted EPS $11.85-$12.10, consensus $12.19 11/10/22 Becton Dickinson reports Q4 adjusted EPS $2.75, consensus $2.74 11/09/22 Notable companies reporting before tomorrow's open 10/07/22 Becton Dickinson issues recall of sterilization containers, WSJ says 09/24/22 Microsoft among dividend stocks to beat inflation, rising rates, Barron's says 08/29/22 Becton Dickinson ordered to pay $4.8M over hernia-mesh claims, Bloomberg says 08/29/22 Becton Dickinson ordered to pay $4.8M over hernia-mesh claims, Bloomberg says 01/03/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/12/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/10/22 Fly Intel: Pre-market Movers 08/29/22 What You Missed On Wall Street On Monday 11/21/22 Early notable gainers among liquid option names on November 21st
Hot Stocks
Becton Dickinson and…
Becton Dickinson and CerTest Biotec have announced Emergency Use Authorization, or EUA, from the FDA for a molecular polymerase chain reaction, or PCR, assay for Mpox virus detection.
Show Hide Related Items >> <<
$259.31 / +4.095 (+1.60%)
01/06/23 BD general counsel Samrat Khichi to leave, Michelle Quin named in acting role 12/14/22 GXO Logistics teams with BD Rowa to optimize storage, retrieval 11/10/22 Becton Dickinson increases quarterly dividend 4.6% to 91c per share 10/18/22 Becton Dickinson, Magnolia announce co-exclusive commercial agreement $259.31 / +4.095 (+1.60%)
01/03/23 BofA BofA downgrades Baxter to Neutral, prefers Becton Dickinson 01/03/23 BofA Becton Dickinson upgraded to Buy at BofA on double digit EPS growth 01/03/23 BofA Becton Dickinson upgraded to Buy from Neutral at BofA 12/12/22 Citi Becton Dickinson upgraded to Neutral from Sell at Citi $259.31 / +4.095 (+1.60%)
11/10/22 Becton Dickinson sees FY23 adjusted EPS $11.85-$12.10, consensus $12.19 11/10/22 Becton Dickinson reports Q4 adjusted EPS $2.75, consensus $2.74 11/09/22 Notable companies reporting before tomorrow's open $259.31 / +4.095 (+1.60%)
10/07/22 Becton Dickinson issues recall of sterilization containers, WSJ says 09/24/22 Microsoft among dividend stocks to beat inflation, rising rates, Barron's says 08/29/22 Becton Dickinson ordered to pay $4.8M over hernia-mesh claims, Bloomberg says 08/29/22 Becton Dickinson ordered to pay $4.8M over hernia-mesh claims, Bloomberg says $259.31 / +4.095 (+1.60%)
01/03/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/12/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/10/22 Fly Intel: Pre-market Movers 08/29/22 What You Missed On Wall Street On Monday $259.31 / +4.095 (+1.60%)
11/21/22 Early notable gainers among liquid option names on November 21st
Hot Stocks
Becton Dickinson…
Becton Dickinson announced that Michelle Quinn has been named acting general counsel of BD, succeeding Samrat Khichi, who has informed the company of his intent to depart BD for a new opportunity, effective February 3. Quinn will be responsible for leading the Law Group at BD. She will report to Tom Polen, chairman, CEO and president of BD and become a member of the BD executive leadership team. Quinn joined BD in 2019 and currently serves as senior vice president, deputy general counsel, and chief ethics and compliance officer.
Show Hide Related Items >> <<
12/14/22 GXO Logistics teams with BD Rowa to optimize storage, retrieval 11/10/22 Becton Dickinson increases quarterly dividend 4.6% to 91c per share 10/18/22 Becton Dickinson, Magnolia announce co-exclusive commercial agreement 10/18/22 Becton Dickinson, Biocorp enter self-administered drug therapies tracking pact 01/03/23 BofA BofA downgrades Baxter to Neutral, prefers Becton Dickinson 01/03/23 BofA Becton Dickinson upgraded to Buy at BofA on double digit EPS growth 01/03/23 BofA Becton Dickinson upgraded to Buy from Neutral at BofA 12/12/22 Citi Becton Dickinson upgraded to Neutral from Sell at Citi 11/10/22 Becton Dickinson sees FY23 adjusted EPS $11.85-$12.10, consensus $12.19 11/10/22 Becton Dickinson reports Q4 adjusted EPS $2.75, consensus $2.74 11/09/22 Notable companies reporting before tomorrow's open 10/07/22 Becton Dickinson issues recall of sterilization containers, WSJ says 09/24/22 Microsoft among dividend stocks to beat inflation, rising rates, Barron's says 08/29/22 Becton Dickinson ordered to pay $4.8M over hernia-mesh claims, Bloomberg says 08/29/22 Becton Dickinson ordered to pay $4.8M over hernia-mesh claims, Bloomberg says 01/03/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/12/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/10/22 Fly Intel: Pre-market Movers 08/29/22 What You Missed On Wall Street On Monday 11/21/22 Early notable gainers among liquid option names on November 21st
On The Fly
Show Hide Related Items >> <<
01/03/23 Macau reports December casino revenue down 56.3% to 3.48B patacas 12/29/22 Nevada reports November statewide gaming win down 7.62% to $1.22B 12/20/22 New Jersey reports November gaming revenue up 0.3% to $441.1M 12/16/22 Gan Sports announces exclusive partnership with WynnBET 12/28/22 Voip-Pal.com announces PTAB denies institution of four IPR petitions 11/29/22 T-Mobile, ExteNet Systems enter digital wireless infrastructure agreement 11/14/22 Third Point buys TJX, exits Cenovus Energy in Q3 11/07/22 Experian, T-Mobile enter $16M multistate settlement over data breaches 10/06/22 Molson Coors announces new partnership with the Professional Pickleball Assoc 09/29/22 Molson Coors expands agreement with Coca-Cola to develop Topo Chico Spirited 11/29/22 Square, Afterpay report over 61M transactions during Black Friday/Cyber Monday 11/16/22 American Express, Square to launch credit card for Square sellers 11/03/22 Block says gross profit up 37% year-over-year in October 09/28/22 Block's Square launches Tap to Pay on iPhone 12/05/22 Syndax: FDA grants Breakthrough Therapy Designation for revumenib 12/05/22 Syndax, Incyte report axatilimab Phase 1/2 data 12/02/22 Syndax names Steve Sabus as Chief Commercial Officer 11/03/22 Syndax lowers FY22 research and development expenses view to $115M-$125M 12/14/22 ConsenSys teams with PayPal for new way to buy crypto in MetaMask 12/07/22 PayPal expands cryptocurrency buy, sell and hold service to Luxembourg 11/16/22 PayPal's Happy Returns unveils new revenue stream for Shopify merchants 11/14/22 Lone Pine adds Autodesk stake, reduces Meta Platforms, Microsoft stakes 12/19/22 M&T Bank's Wilmington Trust to sell CIT business to Madison Dearborn Partners 12/14/22 M&T Bank raises prime rate to 7.5% from 7% 12/14/22 M&T Bank appoints Daryl Bible as CFO, effective 2Q23 11/02/22 M&T Bank increase prime lending rate to 7% from 6.25% 12/19/22 Mondelez to sell developed-market gum business to Perfetti Van Melle for $1.35B 12/12/22 Mondelez, HCL Technologies announce expanded contract 11/07/22 Mondelez doubles down on Cocoa Life program with total investment of $1B by 2030 11/01/22 Mondelez announces three new members to senior management team 08/15/22 Peacock, Lionsgate enter deal for 'John Wick' prequel series 10/18/22 Lionsgate, Autograph partner with Internet Game for 'SAW' games 09/29/22 Lions Gate considers spinning off studio business 09/28/22 STARZ unveils rebrand for international streaming service, STARZPLAY 09/13/22 Lionsgate, Bell Media enter co-development deal 11/21/22 Kraft Heinz appoints Janelle Orozco as chief procurement officer 10/26/22 Kraft Heinz sees FY22 organic net sales up high-single-digit percentage range 09/07/22 Kraft Heinz updates long-term net leverage target ratio to three times 09/07/22 Kraft Heinz highlights long-term financial targets 12/07/22 Hershey announces first bilingual manufacturing facility 10/20/22 Hershey signs new solar power purchase agreement with National Grid Renewables 08/31/22 Hershey names Marlene Creighton as Global Chief Sales Officer 07/28/22 Hershey raises quarterly dividend 15% to $1.036 per share 12/05/22 IHOP and General Mills partner to turn the brand's iconic pancakes into cereal 11/14/22 General Mills director Cordani sells 26,100 common shares 10/03/22 General Mills exec sells $2.0M in common stock 12/06/22 Fox Corp. provides update on potential News Corp. transaction 11/08/22 News Corp. says Special Committee has not decided on pursuit of Fox deal 11/04/22 Fox Corp. 'pleased' with 'fair and favorable outcome' of Flutter arbitration 11/03/22 Fox Corp. partners with FreeWheel for OneFOX inventory 12/21/22 Washington state AG files lawsuits against pharmacy chains over opioid crisis 12/15/22 CVS Health raises quarterly dividend 10% to 60.5c per share 12/12/22 CVS, Walgreens in $10.7B opioid settlement with attorneys general 11/21/22 CVS Health board approves 2022 Repurchase Program for $10B of shares 12/14/22 GXO Logistics teams with BD Rowa to optimize storage, retrieval 11/10/22 Becton Dickinson increases quarterly dividend 4.6% to 91c per share 10/18/22 Becton Dickinson, Magnolia announce co-exclusive commercial agreement 10/18/22 Becton Dickinson, Biocorp enter self-administered drug therapies tracking pact 01/03/23 Truist Truist upgrades PayPal to Buy, sees investors as 'too negative' 01/03/23 Truist PayPal upgraded to Buy from Hold at Truist 12/27/22 Wedbush Wedbush says SpendingPulse data bodes well for Visa, MasterCard, and PayPal 12/13/22 Piper Sandler PayPal assumed with a Neutral at Piper Sandler 01/03/23 Baird Block upgraded to Outperform from Neutral at Baird 12/21/22 Citi Citi cuts Block target but sees 'compelling buying opportunity' 12/13/22 Piper Sandler Block assumed with an Overweight at Piper Sandler 12/12/22 Mizuho Block price target raised to $70 from $69 at Mizuho 01/03/23 Wells Fargo Wells Fargo upgrades Wynn Resorts to Overweight, raises price target to $101 01/03/23 Wells Fargo Wynn Resorts upgraded to Overweight from Equal Weight at Wells Fargo 12/27/22 UBS Macau GGR could be lifted 'significantly' from early 2023, says UBS 12/15/22 Barclays Wynn Resorts price target raised to $97 from $75 at Barclays 01/03/23 Wedbush Wedbush upgrades M&T Bank to Outperform as a defensive safe haven 01/03/23 Wedbush M&T Bank upgraded to Outperform from Neutral at Wedbush 01/03/23 Barclays M&T Bank downgraded to Equal Weight from Overweight at Barclays 12/21/22 DA Davidson M&T Bank initiated with a Neutral at DA Davidson 01/03/23 BofA BofA downgrades Baxter to Neutral, prefers Becton Dickinson 01/03/23 BofA Becton Dickinson upgraded to Buy at BofA on double digit EPS growth 01/03/23 BofA Becton Dickinson upgraded to Buy from Neutral at BofA 12/12/22 Citi Becton Dickinson upgraded to Neutral from Sell at Citi 01/03/23 Evercore ISI CVS Health downgraded to In Line from Outperform at Evercore ISI 11/23/22 Morgan Stanley CVS Health assumed with an Overweight at Morgan Stanley 11/21/22 Credit Suisse CVS Health price target raised to $125 from $117 at Credit Suisse 11/06/22 Raymond James CVS Health price target lowered to $115 from $120 at Raymond James 01/03/23 Wells Fargo Wells Fargo downgrades Molson Coors to Underweight, lowers price target to $45 01/03/23 Wells Fargo Molson Coors downgraded to Underweight from Equal Weight at Wells Fargo 12/06/22 Deutsche Bank Molson Coors downgraded to Sell from Hold at Deutsche Bank 10/10/22 Wedbush Molson Coors initiated with a Neutral at Wedbush 01/03/23 Wolfe Research T-Mobile downgraded to Peer Perform from Outperform at Wolfe Research 01/03/23 Wolfe Research T-Mobile downgraded to Peer Perform from Outperform at Wolfe Research 12/19/22 MoffettNathanson AT&T downgraded to Underperform at MoffettNathanson after 'dramatic bounce' 12/19/22 MoffettNathanson Verizon upgraded to Market Perform at MoffettNathanson after underperformance 06/02/22 Wolfe Research Fox Corp. assumed at Peer Perform from Outperform at Wolfe Research 04/19/22 Rosenblatt Fox Corp. initiated with a Neutral at Rosenblatt 01/03/23 Wolfe Research Lionsgate downgraded to Underperform from Peer Perform at Wolfe Research 01/03/23 Wolfe Research Lionsgate downgraded to Underperform from Peer Perform at Wolfe Research 12/07/22 JPMorgan Lionsgate downgraded to Underweight from Overweight at JPMorgan 09/29/22 Benchmark Lionsgate price target lowered to $18 from $20 at Benchmark 01/02/23 Rosenblatt Rosenblatt reveals 15 best stock ideas for 2023 10/26/22 Truist Lionsgate price target lowered to $11 from $14 at Truist 08/02/22 Truist Lionsgate price target lowered to $14 from $15 at Truist 01/03/23 Wells Fargo Mondelez initiated with an Overweight at Wells Fargo 01/03/23 RBC Capital Mondelez downgraded to Sector Perform from Outperform at RBC Capital 12/20/22 Morgan Stanley Mondelez price target raised to $75 from $69 at Morgan Stanley 12/15/22 Piper Sandler Mondelez price target raised to $77 from $72 at Piper Sandler 01/03/23 Wells Fargo Hershey initiated with an Underweight at Wells Fargo 12/20/22 Morgan Stanley Hershey price target raised to $231 from $224 at Morgan Stanley 12/08/22 UBS Hershey upgraded to Buy from Neutral at UBS 12/06/22 Deutsche Bank Hershey price target raised to $246 from $236 at Deutsche Bank 01/03/23 Wells Fargo General Mills initiated with an Equal Weight at Wells Fargo 12/21/22 RBC Capital General Mills price target raised to $76 from $72 at RBC Capital 12/20/22 Morgan Stanley General Mills price target raised to $73 from $71 at Morgan Stanley 12/15/22 Piper Sandler General Mills price target raised to $95 from $88 at Piper Sandler 01/03/23 Wells Fargo Kraft Heinz initiated with an Equal Weight at Wells Fargo 12/20/22 Morgan Stanley Kraft Heinz price target raised to $41 from $38 at Morgan Stanley 12/06/22 Deutsche Bank Kraft Heinz price target raised to $49 from $47 at Deutsche Bank 11/15/22 Exane BNP Paribas Kraft Heinz initiated with a Neutral at Exane BNP Paribas 01/03/23 BTIG Syndax named Top Pick for first half of 2023 at BTIG 01/03/23 JPMorgan Syndax initiated with an Overweight at JPMorgan 01/02/23 Barclays Barclays views GSK acquisition interest as positive for oncology stocks 12/12/22 H.C. Wainwright Syndax price target raised to $33 from $31 at H.C. Wainwright 11/09/22 Wynn Resorts reports Q3 EPS ($1.27), consensus ($1.00) 11/09/22 Notable companies reporting after market close 08/09/22 Wynn Resorts reports Q2 EPS ($1.14), consensus (94c) 08/09/22 Notable companies reporting after market close 10/27/22 T-Mobile raise FY22 core adjusted EBITDA view to $26.2B-$26.4B from $26B-$26.3B 10/27/22 T-Mobile reports Q3 EPS 40c, consensus 4c 10/27/22 Notable companies reporting after market close 07/27/22 T-Mobile raises FY22 core adjusted EBITDA view to $26B-$26.3B from $25.8B-$26.2B 11/01/22 Molson Coors reports Q3 EPS $1.32, consensus $1.36 08/02/22 Molson Coors reports Q2 EPS $1.19, consensus $1.19 08/01/22 Notable companies reporting before tomorrow's open 11/03/22 Block reports Q3 adjusted EPS 42c, consensus 23c 11/03/22 Notable companies reporting after market close 08/04/22 Block reports Q2 adjusted EPS 18c, consensus 16c 08/04/22 Notable companies reporting after market close 11/03/22 Syndax reports Q3 EPS (58c), consensus (63c) 08/08/22 Syndax reaffirms FY22 research and development expenses view $130M-$140M 08/08/22 Syndax sees Q3 research and development expenses $25M-$30M 08/08/22 Syndax reports Q2 EPS (62c), consensus (65c) 12/07/22 PayPal CEO sees results 'slightly ahead' of EPS guidance 11/03/22 PayPal says plan to deliver FY23 EPS growth of 'no less than 15%' 11/03/22 PayPal sees Q4 EPS $1.18-$1.20, consensus $1.18 11/03/22 PayPal raises FY22 EPS view to $4.07-$4.09, consensus $3.93 10/19/22 M&T Bank reports Q3 EPS $3.83, consensus $4.04 07/20/22 M&T Bank reports Q2 EPS $3.10, consensus $2.70 11/01/22 Mondelez raises FY22 adjusted EPS view to 10% from up mid-to-high single digits 11/01/22 Mondelez reports Q3 adjusted EPS 74c, consensus 69c 11/01/22 Notable companies reporting after market close 07/26/22 Mondelez backs FY22 EPS view up mid-to-high single digits, consensus $2.93 11/03/22 Lionsgate reports Q2 adjusted EPS (12c), consensus (29c) 08/04/22 Lionsgate reports Q1 EPS (53c), consensus (37c) 10/26/22 Kraft Heinz reports Q3 adjusted EPS 63c, consensus 56c 10/25/22 Notable companies reporting before tomorrow's open 09/07/22 Kraft Heinz backs FY22 revenue view up high-single-digit percentage range 11/04/22 Hershey raises FY22 adjusted EPS view to $8.20-$8.27 from $8.05-$8.20 11/04/22 Hershey reports Q3 adjusted EPS $2.17, consensus $2.10 11/03/22 Notable companies reporting before tomorrow's open 12/20/22 General Mills raises FY23 adjusted EPS view to up 4%-6% from up 2%-5% 12/20/22 General Mills reports Q2 adjusted EPS $1.10, consensus $1.06 12/19/22 Notable companies reporting before tomorrow's open 11/01/22 Fox Corp. reports Q1 adjusted EPS $1.21, consensus $1.14 10/31/22 Notable companies reporting before tomorrow's open 08/10/22 Fox Corp. reports Q4 adjusted EPS 74c, consensus 76c 11/02/22 CVS Health sees FY23 adjusted EPS $8.70-$8.90, consensus $9.06 11/02/22 CVS Health raises FY22 revenue view to $309B-$314B from $307B-$312B 11/02/22 CVS Health raises FY22 adjusted EPS view to $8.55-$8.65 from $8.40-$8.60 11/02/22 CVS Health reports Q3 adjusted EPS $2.09, consensus $1.99 11/10/22 Becton Dickinson sees FY23 adjusted EPS $11.85-$12.10, consensus $12.19 11/10/22 Becton Dickinson reports Q4 adjusted EPS $2.75, consensus $2.74 11/09/22 Notable companies reporting before tomorrow's open
